TY - JOUR
T1 - Racial differences in cardiovascular biomarkers in the general population
AU - Hackler, Eddie
AU - Lew, Jeanney
AU - Gore, M. Odette
AU - Ayers, Colby R.
AU - Atzler, Dorothee
AU - Khera, Amit
AU - Rohatgi, Anand
AU - Lewis, Alana
AU - Neeland, Ian
AU - Omland, Torbjorn
AU - De Lemos, James A.
N1 - Funding Information:
The Dallas Heart Study has been supported by grants from the Donald W. Reynolds Foundation and the National Center for Advancing Translational Sciences of the NIH (UL1TR001105). Biomarker measurements for the present study were supported by Roche Diagnostics, Alere, Inc, LipoScience, and Siemens Healthcare Diagnostics, Inc. Funding support for Dr Neeland is provided by grant 1K23DK106520 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institute of Health and by the Dedman Family Scholarship in Clinical Care from UT South-western. Dr Atzler acknowledges the support of the European Union under a Marie Curie Intra-European Fellowship for Career Development. Dr Rohatgi is supported by the National Heart, Lung, and Blood Institute of the NIH under Award Number K08HL118131 and by the American Heart Association under Award Number 15CVGPSD27030013.
Publisher Copyright:
© 2019 The Authors.
PY - 2019/9/17
Y1 - 2019/9/17
N2 - Background-The incidence and clinical manifestations of cardiovascular disease (CVD) differ between blacks and whites. Biomarkers that reflect important pathophysiological pathways may provide a window to allow deeper understanding of racial differences in CVD. Methods and Results-The study included 2635 white and black participants from the Dallas Heart Study who were free from existing CVD. Cross-sectional associations between race and 32 biomarkers were evaluated using multivariable linear regression adjusting for age, traditional CVD risk factors, imaging measures of body composition, renal function, insulin resistance, left ventricular mass, and socioeconomic factors. In fully adjusted models, black women had higher lipoprotein(a), leptin, D-dimer, osteoprotegerin, antinuclear antibody, homoarginine, suppression of tumorigenicity-2, and urinary microalbumin, and lower adiponectin, soluble receptor for advanced glycation end products and N-terminal pro-B-type natriuretic peptide versus white women. Black men had higher lipoprotein(a), leptin, D-dimer, high-sensitivity C-reactive protein, antinuclear antibody, symmetrical dimethylarginine, homoarginine, high-sensitivity cardiac troponin T, suppression of tumorigenicity-2, and lower adiponectin, soluble receptor for advanced glycation end products, and N-terminal pro-B-type natriuretic peptide versus white men. Adjustment for biomarkers that were associated with higher CVD risk, and that differed between blacks and whites, attenuated the risk for CVD events in black women (unadjusted hazard ratio 2.05, 95% CI 1.32, 3.17 and adjusted hazard ratio 1.15, 95% CI 0.69, 1.92) and black men (unadjusted hazard ratio 2.39, 95% CI 1.64, 3.46, and adjusted hazard ratio 1.21, 95% CI 0.76, 1.95). Conclusions-Significant racial differences were seen in biomarkers reflecting lipids, adipokines, and biomarkers of endothelial function, inflammation, myocyte injury, and neurohormonal stress, which may contribute to racial differences in the development and complications of CVD.
AB - Background-The incidence and clinical manifestations of cardiovascular disease (CVD) differ between blacks and whites. Biomarkers that reflect important pathophysiological pathways may provide a window to allow deeper understanding of racial differences in CVD. Methods and Results-The study included 2635 white and black participants from the Dallas Heart Study who were free from existing CVD. Cross-sectional associations between race and 32 biomarkers were evaluated using multivariable linear regression adjusting for age, traditional CVD risk factors, imaging measures of body composition, renal function, insulin resistance, left ventricular mass, and socioeconomic factors. In fully adjusted models, black women had higher lipoprotein(a), leptin, D-dimer, osteoprotegerin, antinuclear antibody, homoarginine, suppression of tumorigenicity-2, and urinary microalbumin, and lower adiponectin, soluble receptor for advanced glycation end products and N-terminal pro-B-type natriuretic peptide versus white women. Black men had higher lipoprotein(a), leptin, D-dimer, high-sensitivity C-reactive protein, antinuclear antibody, symmetrical dimethylarginine, homoarginine, high-sensitivity cardiac troponin T, suppression of tumorigenicity-2, and lower adiponectin, soluble receptor for advanced glycation end products, and N-terminal pro-B-type natriuretic peptide versus white men. Adjustment for biomarkers that were associated with higher CVD risk, and that differed between blacks and whites, attenuated the risk for CVD events in black women (unadjusted hazard ratio 2.05, 95% CI 1.32, 3.17 and adjusted hazard ratio 1.15, 95% CI 0.69, 1.92) and black men (unadjusted hazard ratio 2.39, 95% CI 1.64, 3.46, and adjusted hazard ratio 1.21, 95% CI 0.76, 1.95). Conclusions-Significant racial differences were seen in biomarkers reflecting lipids, adipokines, and biomarkers of endothelial function, inflammation, myocyte injury, and neurohormonal stress, which may contribute to racial differences in the development and complications of CVD.
KW - Biomarker
KW - Endothelial dysfunction
KW - Inflammation
UR - http://www.scopus.com/inward/record.url?scp=85072140803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072140803&partnerID=8YFLogxK
U2 - 10.1161/JAHA.119.012729
DO - 10.1161/JAHA.119.012729
M3 - Article
C2 - 31514563
AN - SCOPUS:85072140803
SN - 2047-9980
VL - 8
SP - 1
EP - 12
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 18
M1 - e012729
ER -